Madrid. February 2006 – Cellerix, a biotechnology company, and the Spanish Innovation Organisation (Empresa Nacional de Innovación, ENISA) signed a participative loan worth 900,000 euros, to be dedicated to Cellerix’s ongoing clinical trials. These funds, awarded by the public company ENISA, a division of the Department of Industry, Tourism and Trade, help Cellerix consolidate its clinical leadership in the use of adipose-derived stem cells. Cellerix is conducting a Phase II trial treating anal fistulas. It is the only company in the world at this stage of development using adult stem cells from adipose tissue as treatment. This product has received orphan status designation by the EMEA for treating this indication in July ’05.
Cellerix, part of the Genetrix Group located in Madrid (Spain), is also developing a skin regeneration product for treating Epidermolysis Bullosa, a rare and currently untreatable illness. By using adult stem cells for therapy, Cellerix offers a real hope to patients suffering from these illnesses to dramatically improve their quality of life, for which there are no satisfactory treatment alternatives.
These types of loans awarded by ENISA allow the Department of Industry, Tourism and Trade to offer invaluable, providing support to companies like Cellerix, by offering these loans at highly discounted interest rates.
About Cellerix Cellerix is a biotechnology company belonging to the Genetrix Group, which actively develops and produces innovative medicines based on the use of stem cells of adult origin. The company is engaged in clinical Phase II trials for the treatment of complex perianal fistulas. Operational since 2001, Cellerix is a clinically-focused cell therapy company. The company has a developing product pipeline, targeting niche indications such as anal fistulas and skin regeneration for Epidermolysis Bullosa.
